Safety and Efficacy of Remimazolam in ASA III and IV Patients Undergoing Colonoscopy

NCT02532647 | Completed Phase 3 Results DMC FDA Drug

• 1 other identifier: CNS7056-015
• Study Type: interventional
• Target: 79
• Locations: 1 country
• Sites: 3

Brief Summary

A prospective, double-blind, randomized, placebo and active controlled, multi-center, parallel group study comparing remimazolam to placebo, with an additional open-label arm for midazolam, in American Society of Anesthesiologists (ASA) Grade III and IV patients (ASA status evaluated by an anesthesiologist not otherwise involved in the study) undergoing a colonoscopy for diagnostic or therapeutic reasons.

Conditions

Colonoscopy

Outcome Measures

Primary Outcomes (1)

• Success Rates of the Procedure

  The success of the procedure, as measured by completion of the colonoscopy procedure, AND no requirement for a rescue sedative medication, AND no requirement of more than 5 doses of study medication within any 15 minute window. (For midazolam: 3 doses within any 12 minute window)

  From first dose of study drug until the end of colonoscopy

Secondary Outcomes (2)

• Time to Start of Procedure

  From the first administration of the study drug to the beginning of the colonoscopy

• Time to Fully Alert

  From the last injection of the study drug AND from end of colonoscopy until the patient has recovered to fully alert

Study Arms (3)

Remimazolam

EXPERIMENTAL

Remimazolam 2.5 - 5.0 mg initially, followed by 1.25 - 2.5 mg top-up doses as required to maintain sedation. Fentanyl pre-treatment: 25-50 μg (or less for elderly/disabled subjects), and 25 μg top-up doses

Drug: Remimazolam

Midazolam

ACTIVE COMPARATOR

Midazolam 1.0 mg initially, followed by 0.5 mg top-up doses as required to maintain sedation. Fentanyl pre-treatment: 25-50 μg (or less for elderly/disabled subjects), and 25 μg top-up doses

Drug: Midazolam

Placebo

PLACEBO COMPARATOR

Placebo administered in double-blind manner. Fentanyl pre-treatment: 25-50 μg (or less for elderly/disabled subjects), and 25 μg top-up doses

Drug: Placebo

Interventions

Remimazolam DRUG

Also known as: CNS7056

Remimazolam

Midazolam DRUG

Also known as: Versed

Midazolam

Placebo DRUG

Placebo

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Male and female patients, aged ≥18, scheduled to undergo a diagnostic or therapeutic colonoscopy (therapeutic procedures may include hemostasis, resection, ablation decompression, and foreign body extraction, for example).
• ASA grade III/IV
• ASA III patients are patients with severe systemic disease eg patients who, in the judgment of the Principal Investigator (PI), have significant enough systemic disease to warrant performing the colonoscopy procedure only in a facility which has post-procedure inpatient capability. ASA III physical status classification encompasses a wide range of potential patient co-morbidities some of which may make the selection of a facility with post-procedure inpatient capability preferable. By definition, ASA III patients have one or more moderate to severe systemic diseases which potentially cause substantial functional limitation. Examples may include poorly controlled diabetes or hypertension, moderate to severe chronic obstructive pulmonary disease, active hepatitis, heart failure or coronary artery disease (including implanted pacemaker and/or stent, recent myocardial infarction) cerebrovascular accident, or end stage renal disease requiring dialysis.
• ASA IV patients are patients with severe systemic disease that is a constant threat to life eg at least one severe disease that is poorly controlled or at end stage; possible risk of death; unstable angina; symptomatic chronic obstructive pulmonary disease; symptomatic chronic heart failure; hepatorenal failure.
• For all female patients, negative result of urine or serum pregnancy test. Additionally, for women with child-bearing potential only, use of birth control during the study period (from the time of consent until all specified observations are completed).
• Patient voluntarily signs and dates an informed consent form (ICF) that is approved by an investigational review board (IRB) prior to the conduct of any study procedure.
• Patient is willing and able to comply with study requirements and will be available for a Follow-up Visit on Day 1 (+ 1 day) and Follow-up Phone call (Day 4 +/- 3 days) after the colonoscopy.

You may not qualify if:

• Patients with a known sensitivity to benzodiazepines, flumazenil, opioids, naloxone, or a medical condition such that these agents are contraindicated.
• Female patients with a positive pregnancy test at screening or baseline and lactating female patients.
• Patients clearly acutely intoxicated with alcohol or drugs of abuse at baseline.
• Patients in receipt of any investigational drug within 30 days or less than 7 half-lives (whichever is longer) before Screening, or scheduled to receive one during the study period.
• Participation in any previous clinical trial with remimazolam.
• Patients with an inability to communicate well with the Investigator, or deemed unsuitable according to the Investigator (in each case providing a reason).

Sponsors & Collaborators

• Paion UK Ltd.: lead
• Premier Research: collaborator

Study Sites (3)

Jupiter Medical Center

Jupiter, Florida, 33458, United States

Location

Indiana University Division of Gastroenterology/Hepatology

Indianapolis, Indiana, 51000, United States

Location

Delta Research Partners Inc

Monroe, Louisiana, 71201, United States

Location

MeSH Terms

Interventions

remimazolam; Midazolam

Intervention Hierarchy (Ancestors)

Benzodiazepines; Benzazepines; Heterocyclic Compounds, 2-Ring; Heterocyclic Compounds, Fused-Ring; Heterocyclic Compounds

Results Point of Contact

• Title: Trial Information
• Organization: PAION UK Ltd

reg_paion@paion.com

Study Officials

• Douglas Rex, MD

  IU Health University Hospital

  PRINCIPAL INVESTIGATOR

Publication Agreements

• PI is Sponsor Employee: No
• Restriction Type: OTHER
• Restrictive Agreement: Yes

Study Design

• Study Type: interventional
• Phase: phase 3
• Allocation: RANDOMIZED
• Masking: DOUBLE
• Who Masked: PARTICIPANT, INVESTIGATOR
• Purpose: SUPPORTIVE CARE
• Intervention Model: PARALLEL
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: August 19, 2015
• First Posted: August 26, 2015
• Study Start: November 1, 2015
• Primary Completion: December 1, 2016
• Study Completion: December 1, 2016
• Last Updated: September 30, 2020
• Results First Posted: January 23, 2019

Record last verified: 2020-09

Locations

US (3)